Binds Drug, Hapten, Hapten--carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/388.9)
  • Computational method for designing chemical structures having common functional characteristics
    Patent number: 6219622
    Abstract: The present invention related to computational methods for designing chemical structures sharing common, useful, functional properties based on specific combinations of steric configuration and binding affinity. More particularly the present invention provides a method for producing computer-simulated receptors which functionally mimic biological receptors. The simulated receptors are designed to exhibit optimized selective affinity for known target molecules. Chemical structures are then generated and evolved to exhibit selective affinity for the simulated receptors.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: April 17, 2001
    Assignee: University of Guelph
    Inventor: Jonathan M. Schmidt
  • Ouabain immunoassay and kit and ouabain labeled with 125I or fluorescent label
    Patent number: 6190921
    Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: February 20, 2001
    Inventors: Pekka Juhani Leppäluoto, Lauri Erkki Olli Vakkuri, Olli Jaakko Vuolteenaho
  • Catalytic antibodies against cocaine and methods of using and producing same
    Patent number: 6184013
    Abstract: This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing concentration in a subject using the antibodies produced.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: February 6, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Kang Zhao
  • Glycyrrhetinic-acid-like factor
    Patent number: 6180762
    Abstract: A human glycyrrhetinic-acid-like factor which inhibits certain enzymes in pathways of steroid hormone degradation is disclosed.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: January 30, 2001
    Inventors: David J. Morris, Syed Abdul Latif
  • Screening methods for the identification of anti-HIV compounds employing a cyclosporine-specific monoclonal antibody that cross-reacts with HIV-1 p24
    Patent number: 6177253
    Abstract: The subject invention provides new uses for novel derivatives of cyclosporine A and antibodies directed thereto. Specifically, the derivatives and antibodies are useful in methods of treating AIDS, methods of purifying the Gag protein of HIV, methods of screening for anti-HIV compounds, and methods for detecting HIV in a subject. The derivatives and antibodies can also be incorporated into a kit useful for screening for anti-HIV compounds.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: January 23, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Bernard F. Erlanger, Bi-Xing Chen
  • Multiassay method for determining the concentrations of antigens and interferants
    Patent number: 6174688
    Abstract: A method of determining the concentration of a sample antigen in the presence of an interferant by (1) running two immunoassays on the sample: one assay where the interferant influences the binding of both the sample antigen and a labeled antigen and a second assay where the interferant influences the binding of the sample antigen but not the labeled antigen; (2) obtaining a plot of the possible sample antigen concentrations versus the possible interferant concentrations corresponding to the readout for the sample for each of the two immunoassays; and (3) determining the sample antigen concentration and the interferant concentration which correspond to the point that appears on both of the immunoassay plots.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: January 16, 2001
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Robert A. Brizzolara
  • Cocaine derivative, protein conjugate thereof, monoclonal antibody producing cell line, method for preparing the cell line and monoclonal antibody
    Patent number: 6174723
    Abstract: A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives. A monoclonal antibody, a monoclonal antibody producing cell line, and a method for producing the monoclonal antibody producing cell line by using the above cocaine-protein conjugate as an immunogen is also described.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: January 16, 2001
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Keiko Yugawa, Nobuyuki Sigetoh, Jinsei Miyazaki, Tadayasu Mitsumata